ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) has earned an average rating of “Buy” from the seven analysts that ...
Scotiabank analyst Louise Chen initiated coverage of ARS Pharmaceuticals (SPRY) with an Outperform rating and $30 price target The firm says ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback